Quest Licenses Epigenomics’ Methylation Marker to Develop Blood-Based CRC Test | GenomeWeb
NEW YORK (GenomeWeb News) - Quest Diagnostics has signed a non-exclusive licensing agreement for Epigenomics’ Septin 9 DNA methylation biomarker with the goal of commercializing a laboratory-developed blood test for colorectal cancer, Epigenomics said today.
 
Epigenomics said that it has demonstrated in “multiple clinical case control studies” with about 3,000 blood samples that methylated DNA of the Septin 9 gene in blood plasma indicates the presence of early-stage colorectal cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.